As an example, a DKK-1 expression increase could be an early phenomenon during multiple myeloma relapse [74], indicating that levels of this protein and their clinical significance can vary according to tumor progression (when) [75,76]. This evidence concerns the gene DKK1 and plasma cell myeloma.